Targeting the TGF-β1/IL-6 pathway has been shown to reduce tumor burden and metastasis in vivo while enhancing neuroblastoma cell sensitivity to chemotherapy, underscoring the therapeutic potential of interrupting this pathway (Louault et al., 2022b). This evidence concerns the gene TGFB1 and neuroblastoma.